A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

NCT07490990 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Disitamab vedotin + Sintilimab + Multimodality radiotherapy

Sponsor

West China Hospital

Collaborators

[object Object]
[object Object]